Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-10-20 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
第四届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the convening and attendance of the fourth board meeting and the approval of the company's 2024 third quarter report. The document explicitly states that the detailed 2024 third quarter report is disclosed separately on the Beijing Stock Exchange information platform and provides a link and announcement number for that report. The current document is short (1013 characters) and serves as an announcement of the board meeting decisions, including the approval of the quarterly report, rather than the report itself. Therefore, it is not the quarterly report (IR) but a board/management information announcement (MANG) about the meeting and resolutions passed. The document also includes legal compliance statements and voting results related to the board meeting, which aligns with the Board/Management Information category.
2024-10-20 Chinese
股票解除限售公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the lifting of stock sale restrictions (解除限售公告) for a company, detailing the number of shares becoming tradable, shareholders involved, and related compliance information. It does not contain financial statements or detailed financial performance data. The document is relatively short (2213 characters) and serves as a regulatory disclosure about share status changes rather than a financial report or earnings release. This fits the category of a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-09 Chinese
第四届董事会第三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the third meeting of the fourth board of directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions, specifically regarding a land purchase proposal by a wholly-owned subsidiary. There is no financial data, earnings information, or detailed report content. The document is clearly a Board/Management Information announcement about board meeting resolutions and decisions, not a full report or financial statement. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is short and it is not an announcement of a report publication, so RPA is not suitable.
2024-10-09 Chinese
关于全资子公司拟购买土地使用权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding its wholly-owned subsidiary's proposed purchase of land use rights. It details the transaction overview, decision-making process, pricing, and risk factors. The document is relatively short (1887 characters) and focuses on a specific capital transaction rather than comprehensive financial data or results. It does not contain financial statements or detailed financial analysis. The content aligns with updates on company fundraising or capital structure changes, specifically a land purchase for business use. Therefore, it fits best under Capital/Financing Update (CAP).
2024-10-09 Chinese
关于投资者关系活动记录表的公告
Investor Presentation Classification · 85% confidence The document is an investor relations activity record from Shanxi Jinbo Bio-Pharmaceutical Co., Ltd., detailing a roadshow event held on September 20, 2024. It includes Q&A about the company's products, market strategy, and future plans. The document is relatively short (1786 characters) and focuses on investor communication rather than financial results or formal reporting. It does not contain financial statements, audit information, or regulatory filings. It is not an earnings release or annual/interim report. The content aligns with an investor presentation or investor relations activity record, but since it is a record of an investor relations event (roadshow) rather than a formal presentation document, the best fitting category is Investor Presentation (IP).
2024-09-22 Chinese
关于参加医药生物行业上市公司2024年度集中路演活动的公告
Investor Presentation Classification · 85% confidence The document is a public announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. about its participation in a 2024 industry roadshow event for pharmaceutical and biological companies. It details the event's date, location, participation method, and contact information. The document does not contain any financial statements, audit information, voting results, or executive changes. It is an announcement about an investor presentation event rather than the presentation itself or a report. The document length is short (1029 characters), and it serves as a notice to investors about the upcoming event and how to participate. Therefore, it fits best under Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on company strategy and market position, even though the actual presentation content is not included here, the announcement is about the presentation event itself, which is typical for IP filings in this context rather than a simple report publication announcement (RPA).
2024-09-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.